AKT1 and hepatocellular carcinoma: Collectively, we demonstrated an intriguing pathway that the activation of the FOXM1-UBE2S-PTEN-p-AKT signaling axis promotes HCC malignant phenotypes, suggesting that UBE2S may be a potential target for the treatment of HCC.